Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  2.50 1.02% 247.50 39,360 09:20:19
Bid Price Offer Price High Price Low Price Open Price
245.00 250.00 247.50 245.00 245.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.04 -20.97 -55.70 79.0
Last Trade Time Trade Type Trade Size Trade Price Currency
09:23:52 O 3,000 250.00 GBX

Reneuron (RENE) Latest News (1)

More Reneuron News
Reneuron Takeover Rumours

Reneuron (RENE) Share Charts

1 Year Reneuron Chart

1 Year Reneuron Chart

1 Month Reneuron Chart

1 Month Reneuron Chart

Intraday Reneuron Chart

Intraday Reneuron Chart

Reneuron (RENE) Discussions and Chat

Reneuron (RENE) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
08:23:53250.003,0007,500.00O
08:20:48250.002,0005,000.00O
08:20:40250.002,5006,250.00O
08:19:36249.003,0007,470.00O
08:19:12248.002,5006,200.00O
View all Reneuron trades in real-time

Reneuron (RENE) Top Chat Posts

DateSubject
17/7/2019
09:20
Reneuron Daily Update: Reneuron Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENE. The last closing price for Reneuron was 245p.
Reneuron Group Plc has a 4 week average price of 187.50p and a 12 week average price of 187.50p.
The 1 year high share price is 332.50p while the 1 year low share price is currently 47p.
There are currently 31,801,617 shares in issue and the average daily traded volume is 163,687 shares. The market capitalisation of Reneuron Group Plc is £77,913,961.65.
13/7/2019
08:09
lauders: I also went back to see the BOD purchases since the capital reorganization took place at the beginning of January 2018. 27 Sept 2018 = Olav Hellebø, Chief Executive Officer - 14,936 @ 66.9p 27 Sept 2018 = Michael Hunt, Chief Financial Officer - 7,462 @ 67p 11 April 2019 = John Berriman, Non-executive Chairman - 80,000 @ 225p 11 April 2019 = Simon Cartmell OBE, NED - 7,758 @ 225.5516p 11 April 2019 = Professor Sir Chris Evans OBE, NED - 4,500 @ 221.5p 11 April 2019 = Dr Mike Owen, NED - 4,237 @ 236p 18 April 2019 = Professor Sir Chris Evans OBE, NED - 10,000 @ 228.7p So highest price 236p and lowest 66.9p. My only buy was around the average of Prof. Evans' purchases. I think that all the purchasers from 11th April on are expecting to benefit a lot more than they are now as the story unfolds. Sure hope so! Last time I did this was on the AMER BB and the BOD there invested a LOT more than the BOD here. In the meantime the share price there has declined pretty significantly despite the prospects, so over the short term BOD purchases don't necessarily mean a thing! Just wanted to post this as a reference for the BOD's "skin in the game" but some of them do have more than shown as they bought more in the years before. Here is a list of total holdings per the 2018 annual report: John Berriman - 10,434 (2018) 10,434 (2017) Olav Hellebø - 6,694 (2018) 6,694 (2107) Michael Hunt - 20,084 (2018) 20,084 (2017) Simon Cartmell OBE - 7,875 (2018) 7,875 (2017) Dr Tim Corn - 2,000 (2018) 2,000 (2017) Dr Claudia D’Augusta 0 (2018) 0 (2017) Professor Sir Chris Evans OBE - 240,105 (2018) 240,105 (2017) Dr Mike Owen - 0 (2018) 0 (2017) If Dr. Claudia buys any and Dr. Mike buys more we should all sit up and pay real attention! Good to see there have been some buys (see first part) this year and towards the end of last year to change the numbers in the last list when released again in the 2019 annual report!
11/7/2019
19:47
bigspuds: By Mark RobinsonWe haven't covered ReNeuron's(RENE) results since the end of 2016, but given the share price has risen by 148 per cent over the past 12 months, an assessment of recent events is in order. In February, the company announced "strongly positive preliminary efficacy data" in relation to clinical trials for its hRPC (human retinal progenitor cells) stem-cell therapy candidate in retinitis pigmentosa, a rare degenerative condition involving a breakdown and loss of cells in the retina.RENE:LSEReNeuron Group PLC1mthToday change-11.82%Price (GBP)242.50All three patients in the study showed "a rapid improvement in vision compared with their pre-treatment baseline". In practical terms, it meant the patients could read an additional four lines of letters on the standard ETDRS (early treatment diabetic retinopathy study) eye chart. Results for all the patients will be presented at the American Academy of Ophthalmology annual meeting in October. Management notes that "an improvement of at least 15 letters from baseline is considered to be clinically meaningful by the US Food and Drug Administration".RENEURON (RENE)   ORD PRICE:248pMARKET VALUE:£79mTOUCH:245-250p12-MONTH HIGH:333pLOW: 48pDIVIDEND YIELD:nilPE RATIO:naNET ASSET VALUE:74pNET DEBT:£26.4mYear to 31 MarTurnover (£000)Pre-tax profit (£m)Earnings per share (p)Dividend per share (p)2015 †30.0-10.3-50.0nil2016 †29.0-12.8-40.0nil2017 †46.0-18.2-49.2nil201843.0-21.0-55.7nil201949.0-17.2-45.2nil% change+14---Ex-div:-   Payment:-   †EPS for 2015-2017 adjusted to take account of capital reorganisationIC ViewReNeuron also commenced patient dosing in the US placebo-controlled Phase IIb clinical trial of its CTX stem-cell therapy candidate in chronic stroke disability, with top-line data from the study due in late 2020. The clinical progress hasn't gone unnoticed. Chinese drugs heavyweight Fosun Pharma has agreed to license the hRPC and CTX therapies as part of a deal worth up to £80m. Financials are of secondary importance as ReNeuron progresses its clinical programme, although N+1 Singer anticipates that cash will run out by March 2022, so it's probable that the gene therapy specialist will be tapping markets at some point.
09/7/2019
11:56
bg23: the companies only worth £80m at this price, woodford holds approx. 34% worth only £27m. I think this is mostly held in the Patient capital fund, but even if it was all held in the income fund, its still only around 0.5% of his last known assets under management - which will undoubtedly take a hit when dealing is allowed. I'd expect some more selling to perhaps clear down the income fund holding, if it has one, but would think Patient capital would retain an interest. realistically, the higher the share price and therefore the market cap, the more institutionally attractive it is. I suspect it would be a lot easier to sell 10% of a £250m market cap company than an £100m company. financial results don't matter, its the trials and deals update that will be moving this around in the coming months
19/6/2019
16:22
martinfrench: still dont also understand why he paid around 5p for what was at the time a rene price of about 3p (rough), when he could have surely got a better deal out of rene?
11/6/2019
05:41
dickbush: Woodford's problems clearly impacting RENE's share price IN THE SHORT TERM. Looks like an opportunity to add. The Chairman bought 80,000 at between 220 and 240p.
10/5/2019
09:37
garth: daf, The point is, they sold at 267p, not 400p or 600p. One has to assume that if they thought the share price was going to get there any time soon they would have waited. Now, of course, we all know that even insiders make poor judgments about share price movements. You pays your money, you make your choice. G.
09/5/2019
13:25
dickbush: Influenced by Wall Street, which is again worrying about trade conflict with China, our Market is declining. RENE has had a run from less than 50p to 325p. Until we get some more, hopefully, good news, the share price is there to be shot at. I'm willing to gamble on the news continuing to be good. So, shorters, do your worst. Just remember that news on further deals could come at any time.
05/5/2019
00:56
lauders: Thanks for that lead daffodil4. After a bit of searching I found it: Https://woodfordfunds.com/funds/holdings/reneuron/ The part you quoted in full: Investment case summary The investment case for ReNeuron revolves around a solid understanding of the company’s technology, fostered through a long relationship with the company and bolstered by encouraging developmental progress. Meanwhile, ReNeuron’s strategy of seeking out-licensing agreements for individual programmes at appropriate points in their development, also appears sensible, from the perspective of shareholder value creation and as an effective way of funding the business towards commercialisation. We believe the share price has consistently and profoundly undervalued the future potential of ReNeuron’s technologies and are very excited about the opportunity that lies ahead for the business.
13/4/2019
04:13
lauders: Https://www.stockopedia.com/articles/reneuron-share-price-hits-a-new-52-week-high-2091/ Making sense of 52 week highs 52 week highs are always good news. But you might be surprised to know that the prices of high performing shares can be slow to move when these companies publish positive earnings news. Studies show it happens because investors are wary about bidding high performing shares any higher (even if they deserve it). This unusual behaviour is down to what the psychologists Amos Tversky and Daniel Kahneman called anchoring-and-adjustment. We form beliefs by using reference points (like share prices). But as new information comes to light (like earnings reports) we're often slow to update our beliefs away from the original anchor point. Evidence shows this tug-of-war usually ends with the ‘new high’ stock actually drifting higher in price over the coming weeks and months. The upward trend is called “post earnings announcement drift”. As the news sinks in, momentum takes over and the price moves higher. A look at Reneuron’s StockReport could offer more insight into what’s driving the momentum in its share price - and whether that might continue. If there is some positive media over the weekend the momentum may continue next week, if not there could be a slight pull back for a few days until people start to "speculate" on the details that could be shared on 26th April: Further read-outs from the patients treated in the Phase 1/2 study will be presented at the 6th Annual Retinal Cell and Gene Therapy Innovation Summit, taking place in Vancouver, Canada, on 26 April 2019. Information regarding this conference may be found at: Https://www.regonline.com/builder/site/default.aspx?EventID=2548135 Also good to see that RENE are being very active when it comes to conferences/events and will be in Kyoto at this event per the website (link below): Https://www.isev.org/page/ISEV2019 Http://www.reneuron.com/news/events/
06/3/2019
09:08
pdt: The following was posted on the othet board this morning by Cadburyhill; Summary of research note this morn by Stifel is below. "Our investment thesis on ReNeuron is that the stock is fundamentally mispriced and that the delivery of positive clinical data from either of its two main assets will prompt either 1) a long overdue re-rating in the market or 2) industry partners to step in and ascribe value where the market does not. The recent impressive Phase II results with hRPCs in retinitis pigmentosa (RP) has sparked a ~70% share price gain, but in the context of our 625p TP and >60p net cash/share, scenario 1 may be starting to play out but there is a long way to go yet. Meanwhile, we expect industry partners, that were interested in licensing the hRPC asset last year, will be evaluating the asset more intensely now in light of the data, while recent M&A activity in the retinal (gene therapy) space - Roche's $4.3bn acquisition of Spark Therapeutics and Biogen's $800m purchase of Nightstar Therapeutics - demonstrates the value that industry players are currently placing on novel (retinal) technologies. Yet ReNeuron's retinal cell approach has much broader potential applicability than mutation-specific gene therapy. Scenario 2 may play out before scenario 1 can take hold. Reiterate Buy." It will be disappointing if it is taken out before value is realised. Woodford has the largest holding but he purchased a lot of that at 500p so not sure he would want to exit at this level after waiting so long ??
Reneuron share price data is direct from the London Stock Exchange
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190717 08:39:20